Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Generic low-molecular-weight heparins: some practical considerations.

Jawed Fareed1, Wendy L Leong, Debra A Hoppensteadt

  • 1Department of Pathology, Loyola University Chicago, Maywood, IL 60153, USA. jfareed@lumc.edu

Seminars in Thrombosis and Hemostasis
|January 5, 2005
PubMed
Summary

Low-molecular-weight heparins (LMWHs) have unique structures affecting their biological actions beyond anticoagulation. Due to these distinct product-specific attributes, generic LMWH substitutes are not recommended without clear regulatory guidelines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thromboinflammation and hemostatic activation drive early mortality risk in pulmonary embolism.

Research and practice in thrombosis and haemostasis·2026
Same author

Enoxaparin, Tinzaparin, and Apixaban Modulate Cancer Cell Procoagulant Activity and Viability: Comparison with Quercetin.

Cancers·2026
Same author

A Comparative Study of Porcine and Ovine Derived Defibrotide: Coagulation Profiles, Molecular Characteristics, and DNA Content.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same author

Circulating Exosomal MicroRNAs as Potential Biomarkers for Pulmonary Embolism.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2026
Same author

Multifactorial thrombotic risk in Evans syndrome: a case report and review of the literature.

Thrombosis journal·2026
Same author

Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review.

British journal of haematology·2026

Area of Science:

  • Pharmacology and Drug Development
  • Biochemistry and Molecular Biology
  • Thrombosis and Hemostasis

Background:

  • Low-molecular-weight heparins (LMWHs) are derived from unfractionated heparin (UFH) through distinct manufacturing processes.
  • These processes impart unique molecular and structural characteristics to each LMWH, such as enoxaparin's specific end-group structures.
  • These structural variations can influence pharmacokinetic profiles and non-anticoagulant biological actions, including interactions with growth factors and cellular components.

Purpose of the Study:

  • To highlight the structural and molecular individuality of different low-molecular-weight heparins (LMWHs).
  • To discuss the implications of these unique attributes on their biological actions and therapeutic effects.
  • To address the challenges and concerns regarding the interchangeability and regulatory approval of generic LMWH products.

Related Experiment Videos

Main Methods:

  • Review and analysis of existing scientific literature on the manufacturing processes and structural characterization of various LMWHs.
  • Examination of the impact of unique structural features on LMWH pharmacokinetics and non-anticoagulant biological activities.
  • Discussion of regulatory perspectives from agencies like the FDA and EMEA regarding LMWH characterization and approval.

Main Results:

  • LMWHs possess distinct molecular and structural attributes determined by their manufacturing processes, influencing their biological profiles beyond anti-Xa and anti-IIa activities.
  • Non-anticoagulant effects, such as modulation of inflammatory processes and cellular functions, contribute significantly to the overall therapeutic outcomes of LMWHs.
  • Current regulatory guidelines and scientific consensus are insufficient to establish the interchangeability of generic LMWH versions with branded products.

Conclusions:

  • Each low-molecular-weight heparin (LMWH) is a distinct drug entity with product-specific molecular and structural characteristics.
  • The individuality of LMWHs extends to their non-anticoagulant biological actions, impacting their overall therapeutic spectrum.
  • Generic LMWH substitutes should not be recommended until robust regulatory guidelines are established for molecular, structural, biological, and clinical validation.